Revolution Medicines, Inc.
(NASDAQ : RVMD)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
SAVACassava Sciences, Inc. -0.45%78.250.0%$189.96m
VRXValeant Pharmaceuticals International, Inc. -1.98%29.2014.1%$171.82m
HZNPHorizon Therapeutics Plc -1.01%91.215.5%$142.01m
JAZZJazz Pharmaceuticals Plc -1.19%175.642.2%$114.63m
ICLRICON plc -1.97%213.324.2%$101.80m
CTLTCatalent, Inc. -1.85%108.512.1%$97.63m
SAGESAGE Therapeutics, Inc. 1.49%55.997.6%$65.80m
UTHRUnited Therapeutics Corp. -1.77%179.1814.0%$65.23m
ARGXargenx SE 0.79%317.410.0%$64.19m
BHCBausch Health Cos., Inc. -2.01%29.190.0%$59.99m
PRGOPerrigo Co. Plc -0.78%47.336.9%$54.44m
PCRXPacira Biosciences, Inc. -2.18%59.149.9%$27.07m
AXSMAxsome Therapeutics, Inc. -0.66%66.101.9%$22.03m
RVMDRevolution Medicines, Inc. -2.76%33.100.0%$21.97m
IRWDIronwood Pharmaceuticals, Inc. 0.83%11.579.6%$20.76m

Company Profile

Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.